Na Tong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Na Tong has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Meilin Wang
Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China
22 shared publications - Zhengdong Zhang
Department of Environmental Genomics, School of Public Health, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, Nanjing 211166, China
22 shared publications - Changjun Yin
Division of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
19 shared publications - Chao Qin
Nanjing Medical University
19 shared publications - Danni Shi19 shared publications
Dongyan Zhong
19 shared publications
Latest Publications
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
MiRNAs play important roles in numerous cellular processes, including development, proliferation, apoptosis, and carcinogenesis. Because altered expression and function of miRNAs has been observed in bladder cancer, we investigated whether genetic variations in miRNAs are associated with bladder cancer risk and prognosis. Using bioinformatics tools, we selected five single-nucleotide polymorphisms located in miRNAs and used these to evaluate miRNA–disease associations in a two-stage model, consisting of 1,019 bladder cancer cases and 1,182 controls (683 cases and 728 controls in the training set and 336 cases and 454 controls in the test set). We found that miR-146a rs2910164 C allele was associated with significantly decreased risk of bladder cancer in both the training and test sets, as well as the combined set [OR = 0.80, 95% confidence interval (CI) = 0.71–0.90, P = 2.92 × 10−4]. Furthermore, the rs2910164 GC/CC genotypes conferred a significantly reduced risk of recurrence, compared with the GG genotype (P = 0.016). Functional analysis revealed that miR-146a rs2910164 C allele inhibited cell proliferation and significantly downregulated expression of IRAK1 and TRAF6 in bladder cancer cells. Additional examination of 64 bladder cancer tissues showed that individuals carrying the C allele had increased expression levels of miR-146a compared with those carrying the G allele (P = 0.010). Taken together, our findings show that miR-146a rs2910164 plays an important role in the risk and recurrence of bladder cancer, suggesting it may represent a biomarker for risk prevention and therapeutic intervention. Further larger and prospective cohorts are needed to validate our findings. Cancer Res; 72(23); 6173–82. ©2012 AACR.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
MiRNAs play important roles in numerous cellular processes, including development, proliferation, apoptosis, and carcinogenesis. Because altered expression and function of miRNAs has been observed in bladder cancer, we investigated whether genetic variations in miRNAs are associated with bladder cancer risk and prognosis. Using bioinformatics tools, we selected five single-nucleotide polymorphisms located in miRNAs and used these to evaluate miRNA–disease associations in a two-stage model, consisting of 1,019 bladder cancer cases and 1,182 controls (683 cases and 728 controls in the training set and 336 cases and 454 controls in the test set). We found that miR-146a rs2910164 C allele was associated with significantly decreased risk of bladder cancer in both the training and test sets, as well as the combined set [OR = 0.80, 95% confidence interval (CI) = 0.71–0.90, P = 2.92 × 10−4]. Furthermore, the rs2910164 GC/CC genotypes conferred a significantly reduced risk of recurrence, compared with the GG genotype (P = 0.016). Functional analysis revealed that miR-146a rs2910164 C allele inhibited cell proliferation and significantly downregulated expression of IRAK1 and TRAF6 in bladder cancer cells. Additional examination of 64 bladder cancer tissues showed that individuals carrying the C allele had increased expression levels of miR-146a compared with those carrying the G allele (P = 0.010). Taken together, our findings show that miR-146a rs2910164 plays an important role in the risk and recurrence of bladder cancer, suggesting it may represent a biomarker for risk prevention and therapeutic intervention. Further larger and prospective cohorts are needed to validate our findings. Cancer Res; 72(23); 6173–82. ©2012 AACR.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 17K, Association between miR-146a rs2910164 and expression of mature miR-146a.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 17K, Association between miR-146a rs2910164 and expression of mature miR-146a.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 22K, Analysis of miR-146a rs2910164 polymorphism association with non-muscle invasive bladder cancer patients' recurrence, stratified by selected variables.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 22K, Analysis of miR-146a rs2910164 polymorphism association with non-muscle invasive bladder cancer patients' recurrence, stratified by selected variables.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF, 18K, Quantitative real-time PCR was used to measure the levels of mature miR-146a expression in transected T24 and EJ cells.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF, 18K, Quantitative real-time PCR was used to measure the levels of mature miR-146a expression in transected T24 and EJ cells.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 22K, Stratified analysis of the association between miR-146a rs2910164 and risk of bladder cancer.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 22K, Stratified analysis of the association between miR-146a rs2910164 and risk of bladder cancer.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legend from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legend from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 21K, Key information on the 14 selected miRNA polymorphisms.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 21K, Key information on the 14 selected miRNA polymorphisms.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 21K, Primers and probes for genotype screening by TaqMan allelic discrimination.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 21K, Primers and probes for genotype screening by TaqMan allelic discrimination.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 355K, Primary information in miRNA SNPs.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Genetic Variants in miRNAs Predict Bladder Cancer Risk and Recurrence
PDF file, 355K, Primary information in miRNA SNPs.